Previous close | 1,673.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 8,263,272 |
Market cap | 69.667B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 14.21 |
EPS (TTM) | 1.20 |
Earnings date | 31 Jul 2024 |
Forward dividend & yield | 0.64 (3.83%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?